For: | Ganzetti G, Campanati A, Molinelli E, Offidani A. Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background. World J Cardiol 2016; 8(2): 120-131 [PMID: 26981209 DOI: 10.4330/wjc.v8.i2.120] |
---|---|
URL: | https://www.wjgnet.com/1949-8462/full/v8/i2/120.htm |
Number | Citing Articles |
1 |
Paul W Caton, Elizabeth A Evans, Michael P Philpott, Rosalind F Hannen. Can the skin make you fat? A role for the skin in regulating adipose tissue function and whole-body glucose and lipid homeostasis. Current Opinion in Pharmacology 2017; 37: 59 doi: 10.1016/j.coph.2017.08.011
|
2 |
Marco Fiore, Sebastiano Leone, Alberto Enrico Maraolo, Emilio Berti, Giovanni Damiani. Liver Illness and Psoriatic Patients. BioMed Research International 2018; 2018: 1 doi: 10.1155/2018/3140983
|
3 |
David Romero‐Pérez, Isabel Belinchón‐Romero, Pablo Bellot, Rubén Francés, Francisco Marco, Jose Manuel Ramos‐Rincón. Nonalcoholic fatty liver disease puts patients with psoriasis at greater cardiovascular risk. Australasian Journal of Dermatology 2019; 60(4) doi: 10.1111/ajd.13098
|
4 |
Anna Campanati, Federico Diotallevi, Emanuela Martina, Matteo Paolinelli, Giulia Radi, Annamaria Offidani. Safety update of etanercept treatment for moderate to severe plaque psoriasis. Expert Opinion on Drug Safety 2020; 19(4): 439 doi: 10.1080/14740338.2020.1740204
|
5 |
Manjunath Ramanjaneya, Ilham Bettahi, Jayakumar Jerobin, Prem Chandra, Charbel Abi Khalil, Monica Skarulis, Stephen Lawrence Atkin, Abdul-Badi Abou-Samra. Mitochondrial-Derived Peptides Are Down Regulated in Diabetes Subjects. Frontiers in Endocrinology 2019; 10 doi: 10.3389/fendo.2019.00331
|
6 |
Kristian Reich, Ulrich Mrowietz, Christina Sorbe, Ralph von Kiedrowski, Sebastian Diemert, Lisa Schaeffer, Natalia Kirsten, Nesrine Ben-Anaya, Matthias Augustin. Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline – a multivariable regression analysis from the German Psoriasis Registry PsoBest. Journal of Dermatological Treatment 2022; 33(8): 3170 doi: 10.1080/09546634.2022.2115285
|
7 |
Luigi Barrea, Giovanna Muscogiuri, Carolina Di Somma, Giuseppe Annunziata, Matteo Megna, Andrea Falco, Anna Balato, Annamaria Colao, Silvia Savastano. Coffee consumption, metabolic syndrome and clinical severity of psoriasis: good or bad stuff?. Archives of Toxicology 2018; 92(5): 1831 doi: 10.1007/s00204-018-2193-0
|
8 |
Misty G. Eleryan, Sophia Akhiyat, Olabola Awosika, Kurt Wenk, Monica Rengifo-Pardo, Lisa W. Martin, Alison Ehrlich. A Case–Control Study to Evaluate Serum Lipoprotein Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis. Journal of Psoriasis and Psoriatic Arthritis 2018; 3(3): 88 doi: 10.1177/2475530318781329
|
9 |
Mercedes Perez-Carreras, Begoña Casis-Herce, Raquel Rivera, Inmaculada Fernandez, Pilar Martinez-Montiel, Victoria Villena. Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach. World Journal of Gastroenterology 2021; 27(41): 7113-7124 doi: 10.3748/wjg.v27.i41.7113
|
10 |
Elisa Molinelli, Claudia Sapigni, Anna Campanati, Valerio Brisigotti, Annamaria Offidani. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa. Expert Opinion on Drug Metabolism & Toxicology 2020; 16(11): 1019 doi: 10.1080/17425255.2020.1810233
|
11 |
R.B. Prussick, L. Miele. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?. British Journal of Dermatology 2018; 179(1): 16 doi: 10.1111/bjd.16239
|
12 |
Müfide Arzu Özkarafakılı, Mustafa İlteriş Bardakçı, Onur Sivaz, İlknur Kıvanç Altunay. Unmasking Pulmonary Parenchymal Changes in Psoriasis Patients: A Radiological Perspective. Medicina 2025; 61(2): 196 doi: 10.3390/medicina61020196
|
13 |
Amanda Pedder. Treating Psoriasis: What Is New About Fumaric Acid Esters?. European Medical Journal 2018; : 25 doi: 10.33590/emj/10314355
|
14 |
Luciana Agoglia, Helena Peixoto, Ana Carolina Cardoso, Lívia Barbosa, Cecília S.X.L. Victer, Sueli Carneiro, Gil F. Salles, Cristiane A. Villela-Nogueira, Maria Chiara Chindamo. Psoriasis and cardiovascular risk: associated and protective factors. Anais Brasileiros de Dermatologia 2025; doi: 10.1016/j.abd.2024.07.013
|
15 |
Carmen Busca Arenzana, Lucía Quintana Castanedo, Clara Chiloeches Fernández, Daniel Nieto Rodríguez, Pedro Herranz Pinto, Ana Belén Delgado Hierro, Antonio Olveira Martín, María Luisa Montes Ramírez. Psoriasis and Liver Damage in HIV-Infected Patients. Cells 2021; 10(5): 1099 doi: 10.3390/cells10051099
|
16 |
Ellie C. Stefanadi, Georgios Dimitrakakis, Christos-Konstantinos Antoniou, Dimitrios Challoumas, Nikita Punjabi, Inetzi Aggeliki Dimitrakaki, Sangeeta Punjabi, Christodoulos I. Stefanadis. Metabolic syndrome and the skin: a more than superficial association. Reviewing the association between skin diseases and metabolic syndrome and a clinical decision algorithm for high risk patients. Diabetology & Metabolic Syndrome 2018; 10(1) doi: 10.1186/s13098-018-0311-z
|
17 |
Deepak MW Balak, Stefano Piaserico, Ismail Kasujee. Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies. Psoriasis: Targets and Therapy 2021; : 151 doi: 10.2147/PTT.S342911
|
18 |
Imke Reese. Langkettige Omega-3-Fettsäuren bei atopischer Dermatitis und Psoriasis. hautnah dermatologie 2016; 32(6): 28 doi: 10.1007/s15012-016-2278-5
|
19 |
Antonio Olveira, Pedro Herranz, María Luisa Montes. Psoriasis and fatty liver: a harmful synergy. Revista Española de Enfermedades Digestivas 2019; 111: 314 doi: 10.17235/reed.2019.6263/2019
|
20 |
Luigi Barrea, Francesca Nappi, Carolina Di Somma, Maria Savanelli, Andrea Falco, Anna Balato, Nicola Balato, Silvia Savastano. Environmental Risk Factors in Psoriasis: The Point of View of the Nutritionist. International Journal of Environmental Research and Public Health 2016; 13(7): 743 doi: 10.3390/ijerph13070743
|
21 |
Giuseppe Dattilo, Francesco Borgia, Claudio Guarneri, Matteo Casale, Roberto Bitto, Claudia Morabito, Salvatore Signorelli, Niki Katsiki, Serafinello P. Cannavò. Cardiovascular Risk in Psoriasis: Current State of the Art. Current Vascular Pharmacology 2018; 17(1): 85 doi: 10.2174/1570161115666171116163816
|
22 |
Ana R. Fernandes, Carlos Martins-Gomes, Antonello Santini, Amélia M. Silva, Eliana B. Souto. Design of Nanostructures for Versatile Therapeutic Applications. 2018; : 379 doi: 10.1016/B978-0-12-813667-6.00009-7
|
23 |
Ivana Mikolasevic, Sandra Milic, Tamara Turk Wensveen, Ivana Grgic, Ivan Jakopcic, Davor Stimac, Felix Wensveen, Lidija Orlic. Nonalcoholic fatty liver disease - A multisystem disease?. World Journal of Gastroenterology 2016; 22(43): 9488-9505 doi: 10.3748/wjg.v22.i43.9488
|
24 |
Jie HU, YaQiong Shao, Cheng Gui, Yihui Xiao, Lixia Li, Zheng Li. Prevalence and risk of nonalcoholic fatty liver disease among adult psoriatic patients: A systematic review, meta-analysis, and trial sequential analysis. Medicine 2024; 103(18): e38007 doi: 10.1097/MD.0000000000038007
|
25 |
Anna Campanati, Matteo Paolinelli, Frederico Diotallevi, Emanuela Martina, Elisa Molinelli, Annamaria Offidani. Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis. Expert Opinion on Drug Metabolism & Toxicology 2019; 15(11): 913 doi: 10.1080/17425255.2019.1681969
|
26 |
Antonio Benedetti, Anna Campanati, Emanuela Martina, Oriana Simonetti, Emanuele Bendia, Antonio Di Sario, Luca Maroni, Marco Marzioni, Irene Pierantonelli, Paola Sassaroli, Laura Schiadà, Gianluca Svegliati-Baroni, Giuseppe Tarantino, Annamaria Offidani. The First Outstanding 50 Years of “Università Politecnica delle Marche”. 2020; : 221 doi: 10.1007/978-3-030-33832-9_16
|
27 |
Neda Adibi, Reza M Robati. Skin and metabolic syndrome. Journal of Research in Medical Sciences 2021; 26(1): 16 doi: 10.4103/jrms.JRMS_585_20
|
28 |
Eveline De Brandt, Tom Hillary. Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management. Psoriasis: Targets and Therapy 2022; : 113 doi: 10.2147/PTT.S293107
|
29 |
Luigi Barrea, Paolo Emidio Macchia, Carolina Di Somma, Maddalena Napolitano, Anna Balato, Andrea Falco, Maria Cristina Savanelli, Nicola Balato, Annamaria Colao, Silvia Savastano. Bioelectrical phase angle and psoriasis: a novel association with psoriasis severity, quality of life and metabolic syndrome. Journal of Translational Medicine 2016; 14(1) doi: 10.1186/s12967-016-0889-6
|
30 |
Yong Tan, Qiu Qi, Cheng Lu, Xuyan Niu, Yanping Bai, Chunyan Jiang, Yang Wang, Youwen Zhou, Aiping Lu, Cheng Xiao. Cytokine Imbalance as a Common Mechanism in Both Psoriasis and Rheumatoid Arthritis. Mediators of Inflammation 2017; 2017: 1 doi: 10.1155/2017/2405291
|
31 |
Chen-Yi Wu, Hsiao-Yun Hu, Chung-Pin Li, Yiing-Jeng Chou, Yun-Ting Chang, Emiliano Giardina. Comorbidity profiles of psoriasis in Taiwan: A latent class analysis. PLOS ONE 2018; 13(2): e0192537 doi: 10.1371/journal.pone.0192537
|
32 |
Elizabeth A. Evans, Sophie R. Sayers, Xenia Kodji, Yue Xia, Mahum Shaikh, Alizah Rizvi, James Frame, Susan D. Brain, Michael P. Philpott, Rosalind F. Hannen, Paul W. Caton. Psoriatic skin inflammation induces a pre-diabetic phenotype via the endocrine actions of skin secretome. Molecular Metabolism 2020; 41: 101047 doi: 10.1016/j.molmet.2020.101047
|
33 |
Imke Reese. Langkettige Omega-3-Fettsäuren bei atopischer Dermatitis und Psoriasis. ästhetische dermatologie & kosmetologie 2017; 9(1): 24 doi: 10.1007/s12634-017-5403-5
|
34 |
Giulia Radi, Anna Campanati, Federico Diotallevi, Giulio Rizzetto, Emanuela Martina, Ivan Bobyr, Melania Giannoni, Annamaria Offidani. Long‐term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real‐world, single‐center experience. Dermatologic Therapy 2021; 34(6) doi: 10.1111/dth.15179
|
35 |
K. A. Rubina, V. Yu. Sysoeva, E. I. Zagorujko, Z. I. Tsokolaeva, M. I. Kurdina, Ye. V. Parfyonova, V. A. Tkachuk. Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas. Archives of Dermatological Research 2017; 309(6): 433 doi: 10.1007/s00403-017-1738-z
|
36 |
S.G. Lykova, M.A. Morzhanaeva, O.B. Nemchaninova, E.V. Svechnikova. Psoriasis in patients with metabolic syndrome: clinical aspects of the problem. Klinicheskaya dermatologiya i venerologiya 2020; 19(2): 214 doi: 10.17116/klinderma202019021214
|
37 |
Suvijak Untaaveesup, Piyawat Kantagowit, Patompong Ungprasert, Nitchanan Kitlertbanchong, Tanyatorn Vajiraviroj, Tanpichcha Sutithavinkul, Gynna Techataweewan, Wongsathorn Eiumtrakul, Rinrada Threethrong, Thanaboon Chaemsupaphan, Walaiorn Pratchyapruit, Chutintorn Sriphrapradang. The Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine 2025; 14(4): 1374 doi: 10.3390/jcm14041374
|